Ovarian Cancer Research Seminar Series

The Rivkin Center and the American Association for Cancer Research co-presented the Virtual Ovarian Cancer Research Seminar Series in the form of weekly presentations during the month of September 2020 in honor of Ovarian Cancer Awareness Month.


Since we were unable to meet in person this year for the 13th Biennial Ovarian Cancer Research Symposium, this Virtual Seminar Series provided an educational opportunity and helped keep our community connected during this time. The goal of the Seminar Series was to bring together clinicians and researchers from across many disciplines and institutions worldwide to share ideas and advance the field of ovarian cancer research. The Seminars sought to enhance the understanding and knowledge of ovarian cancer, discuss the most recent innovations in the field of ovarian cancer research, and address pressing concerns of the leaders in the clinical and research community.

The Seminar speakers and topics were developed by our Planning Committee and were by invitation only. AMA PRA Category 1 Credit(s)TM are available to those who attended the live, virtual activity. For those who were unable to join us live, recordings of the Seminars are available on the Agenda tab or by visiting this YouTube playlist.

  • Detection and Prevention of Ovarian Cancer 
  • DNA Repair and Model Systems
  • Immuno-oncology
  • Novel Therapeutics
Continuing Medical Education Activity AMA PRA Category 1 CreditsTM will be available.

For questions, please contact Jackie Lang at or 206-215-3118.

September 3rd, 2020
Detection and Prevention of Ovarian Cancer

3:00 – 3:30 pm

Barbara Norquist, MD
University of Washington

3:30 – 4:00 pm

Douglas Levine, MD
NYU Langone Health

September 10th, 2020
DNA Repair and Model Systems

3:00 – 3:30 pm

Alan D’Andrea, MD
Dana-Farber Cancer Institute

3:30 – 4:00 pm

Sandra Orsulic, PhD
University of California, Los Angeles

September 17th, 2020

3:00 – 3:30 pm

Kunle Odunsi, MD, PhD
Roswell Park Cancer Institute

3:30 – 4:00 pm

Tyler Curiel, MD, MPH
University of Texas Health, San Antonio

September 24th, 2020
Novel Therapeutics

3:00 – 3:30 pm

Ursula Matulonis, MD
Dana-Farber Cancer Institute

3:30 – 4:00 pm

Elise Kohn, MD
National Cancer Institute


Registration is now closed.

Continuing Medical Education (CME)


This activity has been planned and implemented in accordance with the accreditation requirements of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The American Association for Cancer Research (AACR) and the Rivkin Center. The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) activities for physicians.


AACR has designated this internet live activity for a maximum of 4.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.


Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the online CME Request for Credit Survey by Monday, November 9, 2020. Certificates will only be issued to those who complete the survey. The Request for Credit Survey will be available via a link on the Virtual Ovarian Cancer Research Seminar Series website or via email. Your CME certificate will be sent to you via email after the completion of the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Request for Credit Surveys
September 3rd:
September 10th:
September 17th:
September 24th: 


Approximately 22,000 women in the United States are diagnosed with ovarian cancer every year. The overall 5-year survival rate is only 46% for ovarian cancer, and the rate is markedly lower for advanced stage cancers. Sadly, the survival rates have only improved slightly over 40 years. While ovarian cancer is the most deadly gynecologic cancer, it is underrepresented in both research funding and research participants. Additionally, complicating the difficulty in diagnosing the disease beyond its physical complexities is that ovarian cancer is a rare disease and many providers will have limited access to information on the signs, symptoms, and latest techniques to diagnose the disease.

In this course, we are addressing major needs in ovarian cancer care and research by educating health care providers and researchers in the latest research on improving treatment, early detection, and prevention, as well as promoting a better understanding of the many diseases under the umbrella of ovarian cancer.

  1. Attendees will need access to and updates on the most recent research in a wide array of topics including novel treatment methods, best early detection techniques, basic biology and categorization of the disease, and recent data on risk, prevention, and progression of ovarian cancer.
  2. Attendees will need information on recent trends in specialized fields such as cancer control strategies and immunotherapy to understand the continuum between prevention and cure.
  3. Attendees will need opportunities to network with other experts in the field to initiate collaborations in research and in clinical care.


The Planning Committee has designed this event to benefit the following audiences: basic scientists, epidemiologists, clinical scientists, and clinicians as well as geneticists, public health researchers, nurses, and advocates for ovarian cancer research. This conference encourages the collaboration between professionals with a wide variety of expertise including: gynecologic oncology, medical oncology, pathology, genetics, molecular biology, cell biology, public health, behavioral epidemiology, translational research, patient care, and patient advocacy.

After participating in this CME activity, physicians should be able to:

  1. Define cancer control strategies to detect ovarian cancer at the earliest stages and to prevent the disease
  2. Identify model systems that best recapitulate ovarian cancer
  3. Articulate how DNA Repair and other molecular mechanisms impact ovarian cancer development and treatment
  4. Explain the elements of tumor microenvironment and immunology as they contribute to ovarian cancer growth and as possible targets for treatment
  5. Identify novel therapies against ovarian cancer and assess the response and resistance of new therapies


It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available on the website of this series. 


This activity is supported by Professional Educational Grants from AstraZeneca and GlaxoSmithKline.


Please contact the Office of CME at (215) 440-9300 or

Seminar Series Planning Committee

The purpose of the Planning Committee is to develop the scope and goals of the 13th Biennial Ovarian Cancer Research Symposium. Due to the COVID-19 pandemic, this year’s committee played a key role in shaping our alternative Virtual Ovarian Cancer Research Seminar Series. The members’ collective expertise informed the selection of invited speakers and the identification of the target audience. The Seminar Series sought to enhance the understanding and knowledge of ovarian cancer, especially among junior and young investigators, discuss the most recent innovations in the field of ovarian cancer research, and address the pressing concerns among the leaders of the clinical and research community.

Planning Committee Members:

Douglas Levine, MD


Barbara Norquist, MD

Ursula Matulonis, MD

Kunle Odunsi, MD/PhD

Jackie Lang, PhD
Rivkin Center

Amy Baran, PhD
American Association for Cancer Research


The Rivkin Center gratefully acknowledges our sponsors for this year’s Virtual Ovarian Cancer Research Seminar Series. Without their vital underwriting and dedication, this event would not have been possible. Thank you!

Gold Sponsor

Please visit the Swedish Cancer Institute website.

Silver Sponsors

The Virtual Ovarian Cancer Research Seminar Series is a CME Activity jointly provided by the American Association for Cancer Research and the Rivkin Center.

Color Rivkin Center Logo